Single-dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression.

@article{Kantrowitz2015SingledoseKF,
  title={Single-dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression.},
  author={Joshua T. Kantrowitz and Batsheva Halberstam and James E. Gangwisch},
  journal={The Journal of clinical psychiatry},
  year={2015},
  volume={76 6},
  pages={
          737-8
        }
}
aChange in Hamilton Depression Rating Scale (HDRS) (A) and Beck Depression Inventory (BDI) (B) mixed-model analysis results are noted on figures, with *P < .05 and **P < .01 on a last-observationcarried-forward paired t test (gray bar represents remission cut-off). The relationship between acute improvement after ketamine (day 1) vs improvement after 8 weeks of d-cycloserine treatment (C) is shown in a scatter plot across the HDRS (circle) and the BDI (triangle). 
Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo–control study
TLDR
D-cycloserine may be therapeutically beneficial for patients with TRD who responded to ketamine infusion but have a residual suicidal risk and a superior maintenance of the antisuicidal effect of ketamine was observed in the DCS group than in the placebo group. Expand
Relationship of Brain Glutamate Response to D-Cycloserine and Lurasidone to Antidepressant Response in Bipolar Depression: A Pilot Study
TLDR
Preliminary pilot results require replication but provide further support for a link between antidepressant effect and a decrease in glutamate by the NMDAR antagonist class of antidepressants. Expand
Ineffectiveness of Repeated Intravenous Ketamine Infusions in Treatment-Resistant Depression After a Post-Ketamine Relapse: Time for a Rethink?
TLDR
A growing body of research has provided evidence of the rapid and robust antidepressant effects of subanesthetic doses of ketamine as an off-label indication for nonpsychotic TRD, but these properties are transient in both MDD and bipolar depression. Expand
Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial
The N-methyl-d-aspartate (NMDA) receptor antagonist ketamine is associated with rapid but transient antidepressant effects in patients with treatment resistant unipolar depression (TRD). Based onExpand
Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.
BACKGROUND Antidepressant response to a single subanesthetic dose infusion of the glutamatergic modulator ketamine is transient in most depressed patients; however, a minority continue to experienceExpand
Psychopharmacology and Experimental Therapeutics for Bipolar Depression.
TLDR
This article presents an evidence-based management approach and discusses the off-label uses of currently available treatments and experimental therapeutics under development for bipolar disorder. Expand
Side-effects associated with ketamine use in depression: a systematic review.
TLDR
This is the first systematic review of the safety of ketamine in the treatment of depression after single and repeated doses and suggests a selective reporting bias with limited assessment of long-term use and safety and after repeated dosing. Expand
Treatment Resistant Depression with Loss of Antidepressant Response: Rapid-Acting Antidepressant Action of Dextromethorphan, A Possible Treatment Bridging Molecule.
TLDR
This report appears to be the first report of a rapid-acting effect in unipolar MDD and adds to antidepressant effects observed in the retrospective chart review of 77 patients with Bipolar II Disorder. Expand
Effect of the NMDA receptor partial agonist, d-cycloserine, on emotional processing and autobiographical memory
TLDR
Findings support the suggestion that low-dose DCS increases specific autobiographical memory retrieval and positive emotional memory and underscores the potential role of DCS as an adjunct to cognitive behavioural therapy in depression. Expand
Maintenance Ketamine Therapy for Treatment-Resistant Depression
TLDR
Maintenance ketamine treatments may be an effective way of maintaining treatment response in some ketamine responders and future research is required to determine optimal length of treatment in those who respond to ketamine and to track adverse effects over a longer time. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 15 REFERENCES
A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression.
TLDR
Findings indicate that NMDAR glycine site antagonism may be a cost-effective target for development of mechanistically novel antidepressants. Expand
Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial
TLDR
This study replicated the previous finding that patients with bipolar depression who received a single ketamine infusion experienced a rapid and robust antidepressant response, and found that ketamine rapidly improved suicidal ideation in these patients. Expand
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
TLDR
In patients with treatment-resistant bipolar depression, robust and rapid antidepressant effects resulted from a single intravenous dose of an N-methyl-D-aspartate-receptor antagonist. Expand
Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression
TLDR
Ketamine was associated with a rapid antidepressant effect in TRD that was predictive of a sustained effect and future controlled studies will be required to identify strategies to maintain an antidepressant response among patients who benefit from a course of ketamine. Expand
The psychotropic effects of cycloserine: A new use for an antibiotic
TLDR
The effects of Cycloserine were most pronounced in patients complaining of insomnia, of muscular tension and, to a lesser degree, in those suffering from anorexia and from depression, while the possibility of its use in psychiatric disorders have been discussed. Expand
A new depression scale designed to be sensitive to change.
TLDR
The construction of a depression rating scale designed to be particularly sensitive to treatment effects is described, and its capacity to differentiate between responders and non-responders to antidepressant treatment was better than the HRS, indicating greater sensitivity to change. Expand
N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia?
TLDR
The N MDAR complex represents a convergence point for potential new treatment approaches in schizophrenia aimed at correcting underlying abnormalities in synthesis and regulation of allosteric modulators, as well as more general potentiation of pre- and post-synaptic glutamatergic and NMDAR function. Expand
A RATING SCALE FOR DEPRESSION
  • M. Hamilton
  • Psychology, Medicine
  • Journal of neurology, neurosurgery, and psychiatry
  • 1960
TLDR
The present scale has been devised for use only on patients already diagnosed as suffering from affective disorder of depressive type, used for quantifying the results of an interview, and its value depends entirely on the skill of the interviewer in eliciting the necessary information. Expand
Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis.
TLDR
As countries review and revise their treatment programmes, CS, and potentially TRD, should be included in MDR-TB treatment regimens and adequate information on possible ADRs should be provided to patients, their families and attending health care workers. Expand
Side effects associated with the treatment of multidrug-resistant tuberculosis.
  • T. Törün, G. Güngör, +6 authors K. Tahaoğlu
  • Medicine
  • The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
  • 2005
TLDR
Timely and aggressive management of drug side effects means that high side effect rates in MDR-TB treatment need not compromise success rates, and side effects observed most frequently included ototoxicity. Expand
...
1
2
...